Phibro Animal Health (NASDAQ:PAHC – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.01, FiscalAI reports. Phibro Animal Health had a net margin of 6.57% and a return on equity of 37.86%. The business had revenue of $386.77 million for the quarter, compared to analysts’ expectations of $382.42 million.
Phibro Animal Health Trading Down 9.9%
Shares of NASDAQ:PAHC traded down $3.92 during midday trading on Thursday, hitting $35.52. 217,028 shares of the stock were exchanged, compared to its average volume of 281,555. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of 14.59 and a beta of 0.42. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.27 and a current ratio of 2.96. The business’s 50-day moving average price is $37.16 and its 200 day moving average price is $41.09. Phibro Animal Health has a 12 month low of $28.25 and a 12 month high of $60.08.
Phibro Animal Health Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 16th. Stockholders of record on Wednesday, November 25th will be paid a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Wednesday, November 25th. Phibro Animal Health’s dividend payout ratio (DPR) is presently 19.67%.
Wall Street Analysts Forecast Growth
PAHC has been the topic of a number of research analyst reports. Weiss Ratings raised Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $47.67.
View Our Latest Research Report on Phibro Animal Health
Key Stories Impacting Phibro Animal Health
Here are the key news stories impacting Phibro Animal Health this week:
- Positive Sentiment: Revenue rose 6% year over year to $386.8 million, topping the $382.4 million consensus estimate. Adjusted earnings were $0.79 per share, one cent above expectations. First-quarter results and guidance
- Neutral Sentiment: Net income increased $3.0 million to $29.5 million. However, management maintained its fiscal 2027 financial guidance rather than raising it, which may have limited the impact of the modest earnings beat. First-quarter results and guidance
- Neutral Sentiment: Phibro kept its quarterly dividend at $0.12 per share, payable December 16 to shareholders of record November 25. Dividend announcement
- Negative Sentiment: Shares moved lower despite the slight revenue and earnings beats. The available reports do not specify a cause; investors may have wanted stronger results or an increase to guidance.
About Phibro Animal Health
Phibro Animal Health Corporation develops, manufactures and sells products designed to support the health, nutrition and productivity of food-producing animals. Its offerings include animal health products, vaccines, medicated feed additives, nutritional specialties and performance products used in livestock, poultry and aquaculture.
The company’s products are intended to help prevent and manage disease, improve animal well-being and support efficient food production. Phibro serves producers, veterinarians, feed manufacturers and distributors through a portfolio that includes pharmaceuticals, vaccines, mineral and nutritional supplements, and other feed and water solutions.
Phibro Animal Health markets its products internationally across a broad range of geographic regions, including North America, Latin America, Europe, Asia-Pacific and other global markets.
Featured Stories
- Five stocks we like better than Phibro Animal Health
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
